Drug intelligence / Profile preview

V540D

Development stage: Phase 1
Lead developer: Merck
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V540D is an investigational vaccine developed by Merck Sharp & Dohme to prevent infections caused by human papillomavirus (HPV). It is designed to provide protection against the same nine HPV types as the currently approved GARDASIL 9 vaccine, with the added goal of covering additional HPV types not included in GARDASIL 9. The vaccine is being evaluated for its safety, tolerability, and immunogenicity in healthy adults. Its mechanism of action involves stimulating an immune response against multiple HPV types to reduce the risk of HPV-related cancers and diseases. The vaccine is administered via intramuscular injection and aims to offer broader protection than existing vaccines[1][3][4].

Beyond the preview

Go deeper on V540D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V540D.

Explore the full profile